SAN FRANCISCO — To one side, it’s a story of betrayal and double dealing. To the other, it’s an example of overreaching by a drug company seeking to knock out a competitor.
On Oct. 17, Medivation Inc. and UCLA chemistry professor Michael Jung will face off in San Francisco Superior Court in a trial to determine whether Jung lived up to his end of a 2005 research agreement that led to the development of the new prostate cancer drug, Xtandi.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
